Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.

Warning

This publication doesn't include Faculty of Sports Studies. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Authors

RÁČIL Zdeněk KLAMOVÁ Hana VOGLOVÁ Jaroslava FABER Edgar RÁZGA Filip ŽÁČKOVÁ Daniela BUREŠOVÁ Lucie CETKOVSKÝ Petr MAYER Jiří

Year of publication 2010
Type Article in Periodical
Magazine / Source American Journal of Hematology
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords persistent splenomegaly; CML; CHR
Description Splenomegaly belongs among typical findings on physical examination in patients with newly diagnosed chronic myelogenous leukemia (CML). Its disappearance is a part of achieving complete hematological response (CHR), that is nowadays (when second generation of tyrosine kinase inhibitors are available) of particular interest during imatinib treatment.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.

More info